4DMedical Ltd's stock surged 8.22% during intraday trading on Monday, marking a significant upward movement for the medical imaging technology company.
The sharp rise appears to be driven by multiple positive developments announced just before the trading session. The company received UKCA certification for its Ct:Vq product for clinical use in the United Kingdom, executed a contract with pharmaceutical giant GlaxoSmithKline for lung imaging analytics, and is reportedly being considered for inclusion in the ASX 200 index.
These developments represent significant milestones for 4DMedical, potentially expanding its market reach in the UK, securing a major commercial partnership with GSK, and gaining increased visibility through potential index inclusion.